No Evidence of Intracranial Hypertension in Trekkers with Acute Mountain Sickness When Assessed Noninvasively with Distortion Product Otoacoustic Emissions
Restricted accessResearch articleFirst published online September, 2014
No Evidence of Intracranial Hypertension in Trekkers with Acute Mountain Sickness When Assessed Noninvasively with Distortion Product Otoacoustic Emissions
Olzowy, Bernhard, Simon Abendroth, Gregor von Gleichenstein, Klaus Mees, and Klaus Stelter. No evidence of intracranial hypertension in trekkers with acute mountain sickness when assessed noninvasively with distortion product otoacoustic emissions. High Alt Med Biol 15:364–370, 2014.—Aims: The role of intracranial hypertension in acute mountain sickness (AMS) is a matter of debate. Distortion product otoacoustic emissions (DPOAEs) can be used to monitor the intracranial pressure (ICP) noninvasively with a level decrease at the frequencies f2=1 and 1.5 kHz indicating elevated ICP.
Methods:
DPOAEs (f2=1, 1.5, 2, 3, and 4 kHz), oxygen saturation (Sao2) and the Lake Louise score (LLS) to assess AMS were measured in trekking tourists on the Mount Everest trek in Nepal at 2610 m and 5170 m.
Results:
Paired data of both altitudes could be obtained of 187 subjects. All results are given in mean±SD. Sao2 was 94.8±2.7% at 2610 m and 79.0±6.9% at 5170 m. While at 2610 m, none of the study subjects had AMS (LLS 0.04±0.02), at 5170 m 82 (43.9%) had AMS when defined as LLS>2, and 31 (16.6%) when defined as LLS>4 (LLS 2.8±2.2). DPOAE levels decreased at altitude in all frequencies without a difference between trekkers with AMS and without AMS. Low Sao2 correlated with high LLS. Low Sao2 correlated with larger DPOAE level decrease only at f2=1 kHz, while the other frequencies showed no correlation. DPOAE level decrease and LLS showed no correlation.
Conclusions:
Our data suggest that subjects with AMS symptoms did not have higher ICP compared to healthy subjects. Consequently, it seems unlikely that intracranial hypertension accounts for the symptoms of AMS.
Get full access to this article
View all access options for this article.
References
1.
BaileyDM, BartschP, KnauthM, and BaumgartnerRW. (2009). Emerging concepts in acute mountain sickness and high-altitude cerebral edema: From the molecular to the morphological. Cell Mol Life Sci, 66:3583–3594.
2.
BaileyDM, RoukensR, KnauthM, et al. (2006). Free radical-mediated damage to barrier function is not associated with altered brain morphology in high-altitude headache. J Cereb Blood Flow Metab, 26:99–111.
3.
BartschP, BaileyDM, BergerMM, KnauthM, and BaumgartnerRW. (2004). Acute mountain sickness: Controversies and advances. High Alt Med Biol, 5:110–124.
4.
BeattieRC, KenworthyOT, and LunaCA. (2003). Immediate and short-term reliability of distortion-product otoacoustic emissions. Int J Audiol, 42:348–354.
5.
BukiB, ChomickiA, DordainM, LemaireJJ, WitHP, ChazalJ, and AvanP. (2000). Middle-ear influence on otoacoustic emissions. II: Contributions of posture and intracranial pressure. Hear Res, 140:202–211.
6.
BukiB, GiraudetF, and AvanP. (2009). Noninvasive measurements of intralabyrinthine pressure changes by electrocochleography and otoacoustic emissions. Hear Res, 251:51–59.
7.
ChapmanPH, CosmanER, and ArnoldMA. (1990). The relationship between ventricular fluid pressure and body position in normal subjects and subjects with shunts: A telemetric study. Neurosurgery, 26:181–189.
8.
CiumanRR. (2009). Communication routes between intracranial spaces and inner ear: function, pathophysiologic importance and relations with inner ear diseases. Am J Otolaryngol, 30:193–202.
9.
de KleineE, WitHP, AvanP, and van DijkP. (2001). The behavior of evoked otoacoustic emissions during and after postural changes. J Acoust Soc Am, 110:973–980.
10.
DeppeC, KummerP, GurkovR, and OlzowyB. (2013). Influence of the individual DPOAE growth behavior on DPOAE level variations caused by conductive hearing loss and elevated intracranial pressure. Ear Hear, 34:122–131.
11.
FischerR, VollmarC, ThiereM, BornC, LeitlM, PflugerT, and HuberRM. (2004). No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia, 24:66–71.
12.
FrankAM, AlexiouC, HulinP, JanssenT, ArnoldW, and TrappeAE. (2000). Non-invasive measurement of intracranial pressure changes by otoacoustic emissions (OAEs)—A report of preliminary data. Zentralbl Neurochir, 61:177–180.
13.
HackettPH, and RoachRC. (2001). High-altitude illness. N Engl J Med, 345:107–114.
14.
HansenHC, and HelmkeK. (1997). Validation of the optic nerve sheath response to changing cerebrospinal fluid pressure: Ultrasound findings during intrathecal infusion tests. J Neurosurg, 87:34–40.
15.
IdeR, HaradaT, KanzakiS, SaitoH, HoshikawaM, KawaharaT, and OgawaK. (2010). Physical and physiological effects on otoacoustic emissions in hypobaric hypoxia. ORL J Otorhinolaryngol Relat Spec, 72:225–232.
16.
JanssenT, NiedermeyerHP, and ArnoldW. (2006). Diagnostics of the cochlear amplifier by means of distortion product otoacoustic emissions. ORL J Otorhinolaryngol Relat Spec, 68:334–339.
17.
KallenbergK, BaileyDM, ChristS, MohrA, RoukensR, MenoldE, SteinerT, BartschP, and KnauthM. (2007). Magnetic resonance imaging evidence of cytotoxic cerebral edema in acute mountain sickness. J Cereb Blood Flow Metab, 27:1064–1071.
18.
KisserU, BeckerS, FeddersenB, et al. (2014). Complex level alterations of the 2f-f distortion product due to hypoxia. Auris Nasus Larynx, 41:37–40.
19.
KummerP, JanssenT, HulinP, and ArnoldW. (2000). Optimal L(1)-L(2) primary tone level separation remains independent of test frequency in humans. Hear Res, 146:47–56.
20.
OlzowyB, DeppeC, ArpornchayanonW, CanisM, StriethS, and KummerP. (2010a). Quantitative estimation of minor conductive hearing loss with distortion product otoacoustic emissions in the guinea pig. J Acoust Soc Am, 128:1845–1852.
21.
OlzowyB, von GleichensteinG, CanisM, aand MeesK. (2008a). Distortion product otoacoustic emissions for assessment of intracranial hypertension at extreme altitude?. Eur J Appl Physiol, 103:19–23.
22.
OlzowyB, von GleichensteinG, CanisM, PlesnilaN, and MeesK. (2008b). Complex level alterations of the 2f (1)-f (2) distortion product due to hypoxia in the guinea pig. Eur Arch Otorhinolaryngol, 265:1329–1333.
23.
OlzowyB, von GleichensteinG, CanisM, PlesnilaN, StriethS, DeppeC, and MeesK. (2010b). Level alterations of the 2f (1)-f (2) distortion product due to hypoxia in the guinea pig depend on the stimulus frequency. Eur Arch Otorhinolaryngol, 267:351–355.
24.
PadayachyLC, FigajiAA, and BullockMR. (2010). Intracranial pressure monitoring for traumatic brain injury in the modern era. Childs Nerv Syst, 26:441–452.
25.
RoachRC, and HackettPH. (2001). Frontiers of hypoxia research: Acute mountain sickness. J Exp Biol, 204:3161–3170.
26.
RosinghHJ, WitHP, and AlbersFW. (1998). Limitations of the MMS-10 tympanic displacement analyser. Audiology, 37:1–6.
27.
SchoonmanGG, SandorPS, NirkkoAC, et al. (2008). Hypoxia-induced acute mountain sickness is associated with intracellular cerebral edema: A 3 T magnetic resonance imaging study. J Cereb Blood Flow Metab, 28:198–206.
28.
SteinerLA, and AndrewsPJ. (2006). Monitoring the injured brain: ICP and CBF. Br J Anaesth, 97:26–38.
29.
StocchettiN. (2007). Could intracranial pressure in traumatic brain injury be measured or predicted noninvasively? Almost. Intensive Care Med, 33:1682–1683.
30.
SutherlandAI, MorrisDS, OwenCG, BronAJ, and RoachRC. (2008). Optic nerve sheath diameter, intracranial pressure and acute mountain sickness on Mount Everest: A longitudinal cohort study. Br J Sports Med, 42:183–188.
31.
TannheimerM, ThomasA, and GerngrossH. (2002). Oxygen saturation course and altitude symptomatology during an expedition to broad peak (8047 m). Int J Sports Med, 23:329–335.
32.
VossSE, AdegokeMF, HortonNJ, ShethKN, RosandJ, and SheraCA. (2010). Posture systematically alters ear-canal reflectance and DPOAE properties. Hear Res, 263:43–51.
33.
VossSE, HortonNJ, TabucchiTH, FolowoseleFO, and SheraCA. (2006). Posture-induced changes in distortion-product otoacoustic emissions and the potential for noninvasive monitoring of changes in intracranial pressure. Neurocrit Care, 4:251–257.
34.
WagnerW, HeppelmannG, VontheinR, and ZennerHP. (2008). Test-retest repeatability of distortion product otoacoustic emissions. Ear Hear, 29:378–391.
35.
WestJB. (2004). The physiologic basis of high-altitude diseases. Ann Intern Med, 141:789–800.
36.
WhiteheadML, StagnerBB, McCoyMJ, Lonsbury-MartinBL, and MartinGK. (1995). Dependence of distortion-product otoacoustic emissions on primary levels in normal and impaired ears. II. Asymmetry in L1,L2 space. J Acoust Soc Am, 97:2359–2377.
37.
WiegandC, and RichardsP. (2007). Measurement of intracranial pressure in children: A critical review of current methods. Dev Med Child Neurol, 49:935–941.
38.
WilsonMH, and MilledgeJ. (2008). Direct measurement of intracranial pressure at high altitude and correlation of ventricular size with acute mountain sickness: Brian Cummins' results from the 1985 Kishtwar expedition. Neurosurgery, 63:970–974; discussion 974–975.
39.
WrightAD, ImrayCH, MorrisseyMS, MarchbanksRJ, and BradwellAR. (1995). Intracranial pressure at high altitude and acute mountain sickness. Clin Sci (Lond), 89:201–204.
40.
ZhaoF, and StephensD. (1999). Test-retest variability of distortion-product otoacoustic emissions in human ears with normal hearing. Scand Audiol, 28:171–178.
